top of page
  • Recruiting

NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

Updated: Jun 15, 2022


NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Venetoclax + Kd

venetoclax

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)


A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.


Part 4 of this study is currently enrolling.


Sponsor

AbbVie


Collaborator

Genentech, Inc; Onyx Therapeutics, Inc.


Multiple Locations

International Study